The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Science Année : 2017

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies

Résumé

Since 2012, clinical trials dedicated to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition with monoclonal antibodies (mAbs) have unambiguously demonstrated robust reductions not only in low-density lipoprotein (LDL) cholesterol (LDL-C) but also in lipoprotein (a) [Lp(a)] levels. The scientific literature published prior to those studies did not provide any evidence for a link between PCSK9 and Lp(a) metabolism. More recent investigations, either in vitro or in vivo, have attempted to unravel the mechanism(s) by which PCSK9 mAbs reduce circulating Lp(a) levels, with some showing a specific implication of the LDL receptor (LDLR) in Lp(a) clearance whereas others found no significant role for the LDLR in that process. This elusive pathway appears clearly distinct from that of the widely prescribed statins that also enhance LDLR function but do not lower circulating Lp (a) levels in humans. So how does PCSK9 inhibition with mAbs reduce Lp(a)? This still remains to be established.
Fichier principal
Vignette du fichier
2017 - The complexity of lipoprotein (a) lowering by PCSK9 antibodies.pdf (325.99 Ko) Télécharger le fichier
Origine : Accord explicite pour ce dépôt
Loading...

Dates et versions

hal-01604774 , version 1 (26-01-2018)

Licence

Paternité - Partage selon les Conditions Initiales

Identifiants

Citer

Gilles Lambert, Aurélie Thedrez, Mickael Croyal, Stéphane Ramin-Mangata, David Couret, et al.. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies. Clinical Science, 2017, 131 (4), pp.261-268. ⟨10.1042/CS20160403⟩. ⟨hal-01604774⟩
198 Consultations
377 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More